Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert Bradway
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMGEN
SEC CIK
Corporate docs
Subsidiaries
Amgen (Europe) GmbH • Amgen Canada Inc. • Amgen Fremont Inc. • Amgen Global Finance B.V. • Amgen GmbH • Amgen Ilaç Ticaret Limited • Amgen K-A, Inc. • Amgen Manufacturing, Limited • Amgen Research (Munich) GmbH • Amgen S.A.S. ...
IRS number
953540776
AMGN stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
10-K
2023 FY
Annual report
14 Feb 24
8-K
Amgen Reports Fourth Quarter and Full Year 2023 Financial Results
6 Feb 24
8-K
Amgen Announces Executive Appointments to Accelerate Innovation
14 Dec 23
10-Q
2023 Q3
Quarterly report
31 Oct 23
8-K
Amgen Reports Third Quarter Financial Results
31 Oct 23
S-8
Registration of securities for employees
6 Oct 23
8-K
Amgen Completes Acquisition of Horizon Therapeutics PLC
6 Oct 23
Transcripts
AMGN
Earnings call transcript
2023 Q4
6 Feb 24
AMGN
Earnings call transcript
2023 Q3
31 Oct 23
AMGN
Earnings call transcript
2023 Q2
3 Aug 23
AMGN
Earnings call transcript
2023 Q1
27 Apr 23
AMGN
Earnings call transcript
2022 Q4
31 Jan 23
AMGN
Earnings call transcript
2022 Q3
4 Nov 22
AMGN
Earnings call transcript
2022 Q2
5 Aug 22
AMGN
Earnings call transcript
2022 Q1
28 Apr 22
AMGN
Earnings call transcript
2021 Q3
3 Nov 21
AMGN
Earnings call transcript
2021 Q2
4 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
53.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2279 |
Opened positions | 272 |
Closed positions | 437 |
Increased positions | 817 |
Reduced positions | 883 |
13F shares | Current |
---|---|
Total value | 76.66 tn |
Total shares | 287.63 mm |
Total puts | 1.53 mm |
Total calls | 1.33 mm |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 49.04 mm | $14.13 tn |
STT State Street | 29.46 mm | $8.49 tn |
Primecap Management | 14.59 mm | $4.20 tn |
MS Morgan Stanley | 14.43 mm | $4.16 tn |
Charles Schwab Investment Management | 10.39 mm | $2.99 tn |
WFC Wells Fargo & Co. | 7.49 mm | $2.16 tn |
Capital Research Global Investors | 6.71 mm | $1.93 tn |
T. Rowe Price | 6.56 mm | $1.89 bn |
NTRS Northern Trust | 6.41 mm | $1.85 tn |
BK Bank Of New York Mellon | 5.49 mm | $1.58 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Matthew C. Busch | Common Stock | Payment of exercise | Dispose F | No | No | 268.87 | 146 | 39.26 k | 4,670 |
18 Mar 24 | Robert A Bradway | Common Stock | Payment of exercise | Dispose F | No | No | 268.87 | 20,560 | 5.53 mm | 664,077 |
18 Mar 24 | Gordon Murdo | Common Stock | Payment of exercise | Dispose F | No | No | 268.87 | 6,461 | 1.74 mm | 51,321 |
18 Mar 24 | Griffith Peter H. | Common Stock | Payment of exercise | Dispose F | No | No | 268.87 | 5,168 | 1.39 mm | 34,710 |
18 Mar 24 | Jonathan P Graham | Common Stock | Payment of exercise | Dispose F | No | No | 268.87 | 5,879 | 1.58 mm | 34,232 |
News
How Is The Market Feeling About Amgen?
19 Apr 24
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
17 Apr 24
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
17 Apr 24
TD Cowen Maintains Buy on Amgen, Lowers Price Target to $360
17 Apr 24
Amgen Provides Update Regarding Results Of Phase 2a COURSE Trial For TEZSPIRE; Says Planning Underway For Phase 3 Development Of Tezepelumab In Chronic Obstructive Pulmonary Disease
16 Apr 24
Press releases
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
16 Apr 24
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
9 Mar 24
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
6 Mar 24
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
29 Feb 24
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
19 Feb 24